

- Смирнов В.С., Ленева И.А., Кудрявцева Т.А., Файзуллоев Е.Б., Заплутанов В.А., Петленко С.В., Карташова Н.П., Грacheva A.В., Корчевая Е.Р.** 2021. Возможности подавления цитопатогенного действия коронавируса SARS-CoV-2 по результатам изучения противовирусной активности препарата Цитовир®-3 *in vitro*. Антибиотики и химиотерапия. Т. 66. № 5–6. С. 4. (*Smirnov V.S., Leneva I.A., Kudryavtseva T.A., Fayzulloev E.B., Zaplutanov V.A., Petlenko S.V., Kartashova N.P., Gracheva A.V., Korchevaya E.R.* 2021. Possibilities of suppressing the cytopathogenic effect of SARS-CoV-2 coronavirus according to the results of the antiviral activity of Cytovir®-3 *in vitro* study. *Antibiotics and Chemother.* V. 66. № 5–6. P. 4.)  
<https://doi.org/10.37489/0235-2990-2021-66-5-6-4-10>
- Хавинсон В.Х., Корнеенков А.А., Попович И.Г., Дудков А.В., Кузник Б.И.** 2020. Мета-анализ иммуномодулирующей активности лекарственного пептидного препарата тималина. Современные проблемы здравоохранения и медицинской статистики. № 4. С.108. (*Khavinson V.H., Korneenkov A.A., Popovich I.G., Gudkov A.V., Kuznik B.I.* 2020. Meta-analysis of the immunomodulatory activity of the medicinal peptide drug timalin. Current problems of healthcare and medical statistics. № 4. P.108.)  
<https://doi.org/10.24411/2312-2935-2020-00100>
- Хавинсон В.Х., Линькова Н., Чалисова Н.И., Ивко О.М.** 2021. Тималин: применение для иммунокоррекции и молекулярные аспекты биологической активности. Успехи совр. биол. Т. 141. № 1. С. 25. (*Khavinson V.H., Linkova N., Chalisova N.I., Ivko O.M.* 2021. Timalin: application for immunocorrection and molecular aspects of biological activity. Successes Modern Biol. T. 141. № 1. P. 25.)  
<https://doi.org/10.31857/S0042132420060046>
- Шипицын К.С., Огарков П.И., Смирнов В.С., Жоголев С.Д., Жоголев К.Д.** 2010. Профилактика острых респираторных вирусных инфекций и пневмоний в организованном коллективе. Эпидемиология и инфекционные болезни. № 1. С. 57. (*Shipitsyn K.S., Ogarkov P.I., Smirnov V.S., Zhogolev S.D., Zhogolev K.D.* 2010. Prevention of acute respiratory viral infections and pneumonia in an organized team. *Epidemiol. Infect. Diseases.* № 1. P. 57.)  
<https://doi.org/10.17816/EID40479>
- Beesu M., Caruso G., Salyer A.C., Shukla N.M., Khetani K.K., Smith L.J., Fox L.M., Tanji H., Ohto U., Shimizu T., David S.A.** 2016. Identification of a human toll-like receptor (TLR) 8-specific agonist and a functional pan-tlr inhibitor in 2-aminoimidazoles. *J. Med. Chem.* V. 59. P. 3311.  
<https://doi.org/10.1021/acs.jmedchem.6b00023>
- Beesu M., Malladi S.S., Fox L.M., Jones C.D., Dixit A., David S.A.** 2014. Human toll-like receptor 8-selective agonistic activities in 1-alkyl-1H-benzimidazol-2-amines. *J. Med. Chem.* V. 57. P. 7325. <https://doi.org/10.1021/jm500701q>
- Bui T.M., Wiesolek H.L., Sumagin R.** 2020. ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. *J. Leukoc. Biol.* V. 108. № 3. P. 787–799.  
<https://doi.org/10.1002/JLB.2MR0220-549R>
- Chong D.L.W., Rebeyrol C., José R.J., Williams A.E., Brown J.S., Scotton C.J., Porter J.C.** 2021. ICAM-1 and ICAM-2 are differentially expressed and up-regulated on inflamed pulmonary epithelium, but neither ICAM-2 nor LFA-1: ICAM-1 are required for neutrophil migration into the airways *in vivo*. *Front. Immunol.* V. 12. P. 691.  
<https://doi.org/10.3389/fimmu.2021.691957>
- Eskandari M., Asgharzadeh F., Askarnia-Faal M.M., Naimi H., Avan A., Ahadi M., Vossoughinia H., Gharib M., Soleimani A., Naghibzadeh N., Ferns G., Ryzhikov M., Khazaei M., Hasanian S.M.** 2022. Mebendazole, an anti-helminth drug, suppresses inflammation, oxidative stress and injury in a mouse model of ulcerative colitis. *Sci. Rep.* V. 12. P. 10249. <https://doi.org/10.1038/s41598-022-14420-6>
- Fiore-Gartland A., Panoskaltsis-Mortari A., Agan A.A., Mistry A.J., Thomas P.G., Matthay M.A., PALISI PICFlu Investigators: Hertz T., Randolph A.G.** 2017. Cytokine profiles of severe influenza virus-related complications in children. *Front. Immunol.* V. 8. P. 1423.  
<https://doi.org/10.3389/fimmu.2017.01423>
- Guo F., Mead J., Aliya N., Wang L., Cuconati A., Wei L., Li K., M. Block T., Guo J.-T., Chang J.** 2012. RO 90-7501 enhances TLR3 and RLR agonist induced antiviral response. *PLoS One.* V. 7. P. e42583.  
<https://doi.org/10.1371/journal.pone.0042583>
- Matsushima K., Yang D., Oppenheim J.J.** 2022. Interleukin-8: an evolving chemokine. *Cytokine.* V. 153. P. 155828.  
<https://doi.org/10.1016/j.cyto.2022.155828>
- Moser T., Hoepner L., Schwenker K., Seiberl M., Feige J., Akgün K., Haschke-Becher E., Ziemssen T., Sellner J.** 2021. Cladribine alters immune cell surface molecules for adhesion and co-stimulation: further insights to the mode of action in multiple sclerosis. *Cells.* V. 10. № 11. P. 3116.  
<https://doi.org/10.3390/cells10113116>
- Kaneko N., Kurata M., Yamamoto T., Morikawa S., Masumoto J.** 2019. The role of interleukin-1 in general pathology. *Inflamm. Regener.* V.3 9. P. 12.  
<https://doi.org/10.1186/s41232-019-0101-5>
- Khalil B.A., Eleamam N.M., Maghazachi A.A.** 2021. Chemokines and chemokine receptors during COVID-19 infection. *Computational and Structural Biotechnol. J.* V. 19. P. 976.  
<https://doi.org/10.1016/j.csbj.2021.01.034>
- Malainou C., Herold S.** 2019. [Influenza]. *Internist (Ber.).* V. 60. P. 1127.  
<https://doi.org/10.1007/s00108-019-00670-6>
- Markey K.A., Gartlan K.H., Kuns R.D., MacDonald K.P., Hill G.R.** 2015. Imaging the immunological synapse between dendritic cells and T cells. *J. Immunol. Methods.* V. 423. P. 40.  
<https://doi.org/10.1016/j.jim.2015.04.029>
- Oudemans-van Straaten H.M., Spoelstra-de Man A.** ME and de Waard M.C. 2014. Vitamin C revisited. *Critical Care.* V. 18. P. 460.  
<https://doi.org/10.1186/s13054-014-0460-x>
- Soema P.C., Kompijer R., Amorij J.P., Kersten G.F.** 2015. Current and next generation influenza vaccines: formulation and production strategies. *Eur. J. Pharm. Biopharm.* V. 94. P. 251.  
<https://doi.org/10.1016/j.ejpb.2015.05.023>
- Ullah A., Al Kury L.T., Althobaiti Y.S., Ali T., Shah F.A.** 2022. Benzimidazole derivatives as new potential NLRP3 inflamasome inhibitors that provide neuroprotection in a rodent model of neurodegeneration and memory impairment. *J. Inflamm. Res.* V. 15. P. 3873.  
<https://doi.org/10.2147/JIR.S351913>
- Van Meerloo J., Kaspers G.J.L., Cloos J.** 2011. Cell sensitivity assays: the MTT assay. *Methods Mol. Biol.* V. 731. P. 237.  
[https://doi.org/10.1007/978-1-61779-080-5\\_20](https://doi.org/10.1007/978-1-61779-080-5_20)
- Zhang Y., Liu H., Tang W., Qiu Q., Peng J.** 2020. Resveratrol prevents TNF-α-induced VCAM-1 and ICAM-1 upregulation in endothelial progenitor cells via reduction of NF-κB activation. *J. Int. Med. Res.* V.48. P. 300060520945131.  
<https://doi.org/10.1177/0300060520945131>

## The Effect of Drugs with Alpha-Glutamyl-Tryptophan *in vitro* on Cytokine Secretion and Level of Surface Molecule ICAM-1

E. G. Golovacheva<sup>a, \*</sup>, E. A. Starikova<sup>b, c</sup>, T. A. Kudryavtseva<sup>b</sup>, and V. A. Apryatina<sup>d</sup>

<sup>a</sup>Smorodintsev Influenza Research Institute of the Ministry of Health of Russia, St. Petersburg, 197376 Russia

<sup>b</sup>Research Institute of Experimental Medicine of the North-Western Branch of the Russian Academy of Medical Sciences, St. Petersburg, 197376 Russia

<sup>c</sup>Department of Immunology of Pavlov First State St. Petersburg Medical University, Saint Petersburg, 197022 Russia

<sup>d</sup>Saint Petersburg Institute of Bioregulation and Gerontology, St. Petersburg, 197110 Russia

\*e-mail: okdixi@mail.ru

The study of the molecular mechanisms underlying the action of immunomodulatory drugs is relevant to substantiate their therapeutic effect. In this work, a comparative analysis of spontaneous and TNFa-induced secretion of proinflammatory cytokines IL-1a and IL-8, as well as the level of the adhesion molecule ICAM-1 in the culture of endothelial cells EA.hy 926 and on peripheral blood mononuclear cells of healthy donors *in vitro* in the model of inflammation when cultivated in the presence of alpha-glutamyl-tryptophan ( $\alpha$ -Glu-Trp) and the drug Cytovir-3 is shown. The aim was to study the cellular mechanisms mediating the immunomodulatory effect of the drugs  $\alpha$ -Glu-Trp and Cytovir-3. It was shown that  $\alpha$ -Glu-Trp reduced TNFa-induced IL-1a production and enhanced the TNFa-stimulated level of the ICAM-1 surface molecule of endothelial cells. At the same time, the drug reduced the secretion of TNFa-induced cytokine IL-8 and increased the spontaneous level of ICAM-1 on mononuclear cells. The drug Cytovir-3 had an activating effect on endothelial cells EA.hy 926 and mononuclear leukocytes of human peripheral blood. In his presence, there was an increase in spontaneous secretion of IL-8 by endothelial and mononuclear cells. The drug also increased the level of TNFa-induced ICAM-1 on endothelial cells and increased the spontaneous level of this surface molecule on mononuclears. Suppression of stimulated production of proinflammatory cytokines under the action of  $\alpha$ -Glu-Trp independently and as part of Cytovir-3 may cause its anti-inflammatory properties. However, an increase in the level of the ICAM-1 surface molecule indicates mechanisms that increase the functional activity of the studied cells, which is equally important for the implementation of an effective immune response to infection and repair of damaged tissues during inflammatory reactions.

**Keywords:** alpha-glutamyl-tryptophan, Cytovir-3, EA.hy 926 endothelial cells, human peripheral blood mononuclear leukocytes, ICAM-1, cytokine secretion, ARVI